The Role of Myeloid Cell-Specific Ten-Eleven Translocase 2 (TET2) in Regulation of Neuroinflammation
骨髓细胞特异性 10-11 转位酶 2 (TET2) 在神经炎症调节中的作用
基本信息
- 批准号:10378505
- 负责人:
- 金额:$ 3.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2022-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAggressive Clinical CourseAnimal ModelAnti-Inflammatory AgentsAntigen PresentationAutoimmuneBlocking AntibodiesBloodBone MarrowCD4 Positive T LymphocytesCD86 geneCNS autoimmune diseaseCNS autoimmunityCell physiologyCellsCellular InfiltrationChIP-seqClinicalCytokine ActivationCytosineDNADataDemyelinationsDevelopmentDioxygenasesDiseaseDown-RegulationEnterobacteria phage P1 Cre recombinaseEnzymesEpigenetic ProcessEtiologyExperimental Autoimmune EncephalomyelitisFamilyFlow CytometryFluorescence-Activated Cell SortingFrequenciesGene ExpressionGeneticGenetic Predisposition to DiseaseGenetic TranscriptionGoalsImmunohistochemistryIn VitroInflammationInflammatoryInterleukin-1 betaInterleukin-4Interleukin-6Knock-outLaboratoriesLeadMalignant NeoplasmsMeasuresMediatingMethylationMicroarray AnalysisModificationMultiple SclerosisMultiple Sclerosis LesionsMusMyelinMyelogenousMyeloid Cell ActivationMyeloid CellsNervous System TraumaNeuraxisNucleic Acid Regulatory SequencesOutcomePTPRC genePathogenesisPathologicPathologyPathway interactionsPatientsPeripheral Blood Mononuclear CellPhagocytosisPhenotypePlayPopulationProductionPropertyRegulationReporterResearchRoleSeveritiesSpleenSusceptibility GeneSystemTamoxifenTimeTranscriptTransgenic Micealpha ketoglutaratecentral nervous system demyelinating disorderchemokineconditional knockoutcytokinedemethylationdisabilityexperiencegenetic risk factorinterestloss of function mutationmembermouse modelmultiple sclerosis patientmultiple sclerosis treatmentneuroimmunologyneuroinflammationneuropathologyneurotoxicitynew therapeutic targetnoveloxidationprogrammed cell death ligand 1promotersingle-cell RNA sequencingtherapeutic targettranslocase
项目摘要
PROJECT SUMMARY
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) believed
to be autoimmune in etiology. Analysis of MS lesions, as well as studies in experimental autoimmune
encephalomyelitis (EAE), a murine model of MS, have indicated that myeloid cells are likely a critical component
of the pathogenesis of CNS autoimmunity. Recently, Ten-Eleven Translocase 2 (TET2) was identified as a
genetic susceptibility locus for MS. TET2 is a Fe(III)-, α-ketoglutarate-dependent enzyme that catalyzes the
oxidation of methylated cytosine to 5’-hydroxymethyl cytosine (5hmC) and promotes active demethylation. 5hmC
is a stable epigenetic mark that can either activate or repress gene expression in a cell- and loci-dependent
manner. There is growing evidence that TET2 acts as a negative regulator of myeloid cell activation and function,
promoting a homeostatic or anti-inflammatory cell state. My hypothesis is that TET2 restrains the pro-
inflammatory functions of myeloid cells to limit inflammation, neurological damage, and disability during CNS
autoimmunity. Supporting this hypothesis, TET2 and 5hmC were found to be reduced in peripheral blood
mononuclear cells of MS patients when compared with controls. Preliminary data from our laboratory
demonstrates that the reduction of TET2 and 5hmC in peripheral blood mononuclear cells is recapitulated in
EAE, and that TET2 transcripts and 5hmC content are further reduced in CNS-infiltrating myeloid cells compared
with the periphery. Additionally, adoptive transfer of encephalitogenic Th17 cells into Tet2+/- mice led to an
exacerbated clinical course compared with Tet2+/+ mice. To continue addressing my hypothesis, I will first
examine the impact of TET2 deficiency in myeloid cells on clinical and pathological outcomes of EAE (Aim 1). I
will do this by examining the EAE disease course, pathology, and cellular infiltration in mice where Tet2 is
knocked out specifically in myeloid cells using a Cre/lox genetic system. Additionally, I will identify the targets of
TET2 in CNS-infiltrating myeloid cells, such as the suppression of pro-inflammatory cytokine production and the
conversion of myeloid cells from a pro-inflammatory phenotype to an anti-inflammatory phenotype (Aim 2).
Completion of these aims will contribute to the fields of neuroimmunology and epigenetics by exploring a novel
mechanism of myeloid cell regulation during CNS autoimmunity, and may lead to the discovery of novel myeloid
cell-specific therapeutic targets for the treatment of MS and related disorders.
项目摘要
多发性硬化(MS)是中枢神经系统(CNS)的炎性脱髓鞘疾病,
是自身免疫性疾病MS病变的分析,以及实验性自身免疫性
脑脊髓炎(EAE),MS的鼠模型,已经表明髓样细胞可能是关键组分
中枢神经系统自身免疫的发病机制。最近,10 - 11易位酶2(TET 2)被鉴定为一种具有生物学活性的蛋白。
TET 2是一种Fe(III)-,α-酮戊二酸依赖性酶,催化MS的遗传易感性位点。
甲基化胞嘧啶氧化为5 '-羟甲基胞嘧啶(5 hmC),并促进主动去甲基化。5hmC
是一种稳定的表观遗传标记,可以激活或抑制细胞和基因座依赖性的基因表达,
方式越来越多的证据表明TET 2作为骨髓细胞活化和功能的负调节剂,
促进体内平衡或抗炎细胞状态。我的假设是TET 2抑制了亲-
骨髓细胞的炎症功能,以限制CNS期间的炎症、神经损伤和残疾
自身免疫支持这一假设,TET 2和5 hmC被发现在外周血中减少
MS患者的单核细胞与对照组相比。我们实验室的初步数据
表明外周血单个核细胞中TET 2和5 hmC的减少在
EAE,TET 2转录物和5 hmC含量在CNS浸润的髓样细胞中进一步降低,
与外围。此外,致脑炎性Th 17细胞过继转移到Tet 2 +/-小鼠中导致了
与Tet 2 +/+小鼠相比,临床病程加重。为了继续阐述我的假设,我将首先
检查髓系细胞中TET 2缺陷对EAE临床和病理结果的影响(目的1)。我
将通过检查Tet 2表达的小鼠的EAE病程、病理学和细胞浸润来实现这一点。
使用Cre/lox遗传系统在骨髓细胞中特异性敲除。此外,我将确定的目标,
TET 2在CNS浸润性髓样细胞中的作用,如抑制促炎细胞因子的产生和
骨髓细胞从促炎表型转化为抗炎表型(目的2)。
这些目标的完成将有助于神经免疫学和表观遗传学领域探索一种新的
中枢神经系统自身免疫过程中髓样细胞调节的机制,并可能导致发现新的髓样细胞免疫抑制剂。
用于治疗MS和相关病症的细胞特异性治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ashley Munie Gardner其他文献
Ashley Munie Gardner的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ashley Munie Gardner', 18)}}的其他基金
The Role of Myeloid Cell-Specific Ten-Eleven Translocase 2 (TET2) in Regulation of Neuroinflammation
骨髓细胞特异性 10-11 转位酶 2 (TET2) 在神经炎症调节中的作用
- 批准号:
10228836 - 财政年份:2021
- 资助金额:
$ 3.23万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 3.23万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 3.23万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 3.23万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 3.23万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 3.23万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 3.23万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 3.23万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 3.23万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 3.23万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 3.23万 - 项目类别: